Bioluminescence imaging (BLI) showed a lower tumor burden in mice treated with BCMA-CD38 CAR-T cells as compared with T cells on d14 (P < 0.001) and d28 (P = 0.002) (Fig. 1E). Here, CD38 is linked to neoplasm.